Role of Toll-like receptors in gastrointestinal malignancies

被引:0
作者
M Fukata
M T Abreu
机构
[1] Inflammatory Bowel Disease Center,Division of Gastroenterology, Department of Medicine
[2] Mount Sinai School of Medicine,undefined
来源
Oncogene | 2008年 / 27卷
关键词
Toll-like receptor; cancer; stomach; intestine; colon; inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
Mounting evidence supports the tenet that innate immune responses to luminal microbes participate in the development of gastrointestinal malignancies. The gastrointestinal tract is relatively unique in that it has evolved in the presence of diverse enteric microflora. Intestinal flora is required to develop a normal adaptive immune response in the periphery. With the characterization of the innate immune system, we have begun to understand the adaptations the intestine has made to the microbiota. The interaction between the microbiota and the intestinal mucosa through Toll-like receptors (TLRs) is required to maintain intestinal homeostasis. In particular, intestinal epithelial cells and lamina propria mononuclear cells such as antigen-presenting cells and T cells must respond to breaches in the mucosal barrier by activating TLR-dependent pathways that result in increased epithelial proliferation, wound healing and recruitment of acute inflammatory cells. In the setting of chronic inflammation such as Helicobacter pylori (H. pylori) infection in the stomach or idiopathic inflammatory bowel disease, the process of repair may eventually result in carcinogenesis. The following review highlights human and animal data that support a role for innate immune responses and TLRs specifically in promoting gastrointestinal malignancies. Candidate pathways linking TLRs to gastrointestinal malignancies include activation of nuclear factor-κB and cyclooxygenase-2. Studying the link between innate immune signaling and gastrointestinal malignancies offers the possibility to identify novel ways to both prevent and treat gastrointestinal cancer.
引用
收藏
页码:234 / 243
页数:9
相关论文
共 565 条
[1]  
Abreu MT(2005)TLR signaling in the gut in health and disease J Immunol 174 4453-4460
[2]  
Fukata M(2001)Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide J Immunol 167 1609-1616
[3]  
Arditi M(2006)Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 355 885-895
[4]  
Abreu MT(2004)Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B J Immunol 172 2522-2529
[5]  
Vora P(2006)Molecular biology of Barrett's cancer Best Pract Res Clin Gastroenterol 20 813-827
[6]  
Faure E(2004)Cancer: an inflammatory link Nature 431 405-406
[7]  
Thomas LS(2007)Structural characterisation and expression analysis of Toll-like receptor 2 gene from catfish Fish Shellfish Immunol 22 418-426
[8]  
Arnold ET(2002)Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid Inflamm Bowel Dis 8 356-361
[9]  
Arditi M(2006)Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 873-884
[10]  
Arber N(2006)Microsatelite GT polymorphism in the Toll-like receptor 2 is associated with colorectal cancer Clin Genet 70 156-160